GHRP-2 (5mg / 10mg)

4.9 stars

$42.00$45.00

5mg
10mg

Earn up to 45 Points.

SKU: N/A Category:

Size Options: 10mg/5mg Composition: Fragment 176-191 Form: Lyophilized Powder Purity: >99% Product Code: P-FRAG176-191

Enjoy Complimentary Shipping on Orders Over $200

Receive a Free 30ml Bac Water with Orders Over $200

Discounts Available for Larger Quantities

Description

GHRP-2 (5mg / 10mg)

GHRP-2 is a synthetic peptide designed to mimic the actions of the naturally occurring peptide ghrelin. Ghrelin, originally discovered in the stomach and composed of 28 amino acids, plays a vital role in regulating various physiological processes, including food intake, the release of growth hormone (HGH), and wound healing.

Research on GHRP-2 suggests its multifaceted impacts on the body. It may act on pituitary cells, stimulating the secretion of growth hormone (GH). Additionally, GHRP-2 has shown the potential to interact with the growth hormone release factor (GRF) receptor. Moreover, it may influence calcium channels, promoting the secretion of both calcium and GH through calcium influx. Furthermore, GHRP-2 has been investigated for its ability to stimulate the cAMP pathway and protein kinase C, potentially resulting in increased calcium influx and subsequent growth hormone secretion. These complex mechanisms underline the diverse effects of GHRP-2.

Research and Clinical Studies

GHRP-2 Peptide and GH Activity

A clinical investigation aimed to understand the impact of two synthetic GHRPs, GHRP-2 and Hexarelin (HEX), on the concentrations of growth hormones, prolactin, adrenocorticotropic hormone (ACTH), and cortisol. Two groups of subjects participated: one group aged between 22 and 27 years, and the other between 66 and 73 years. Both groups received correlated concentrations of both peptides. The results indicated a positive correlation between peptide concentration and GH release in the subjects.

GHRP-2 Peptide and Appetite

In a separate clinical study, seven male subjects were divided into two groups, with one group receiving GHRP-2 and the other receiving saline. Following this, they were presented with a buffet meal to assess their food intake. Researchers reported that subjects who received GHRP-2 consumed an average of 36% more food compared to the saline group. Additionally, GH levels exhibited significant increases in the GHRP-2 group when compared to the saline group.

GHRP-2 Peptide and GH Deficiency

The insulin tolerance test (ITT) is a common diagnostic tool for GH deficiency but may pose contraindications. Another clinical study aimed to explore GHRP-2’s potential as an alternative diagnostic resource for GH deficiency. The study involved 135 subjects initially tested via ITT, with 77 demonstrating normal insulin tolerance and 58 showing GH peak levels of less than three. After overnight fasting, all subjects received GHRP-2. Blood samples collected after 2 hours revealed that GH levels peaked after one hour of GHRP-2 administration in all subjects, with reproducible results upon test repetition. Another clinical study investigated the diagnostic properties of GHRP-2 on young subjects with GH deficiency (GHD) compared to conventional compounds. In this study, 24 subjects with GHD were enrolled. All subjects received at least one conventional compound followed by GHRH and GHRP-2. Notably, GHRP-2 administration led to significantly increased serum GH levels in these subjects. Furthermore, 21 subjects who exhibited a robust response to the peptide were subsequently presented with a combination of GHRP-2 and GHRH, resulting in a positive response in their GH levels.

Combination Studies with TRH and GnRH

A clinical study examined subjects with prolonged hypo-somatotropism, hypogonadism, or hypothyroid complications to evaluate the effects of GHRP-2, Thyrotropin-releasing hormone (TRH), and Gonadotropin-releasing hormone (GnRH) compounds. These compounds were administered alone or in combination with GHRP-2. The study included 33 male subjects who received various treatments over 5 days. Serum samples were collected on the first and last nights of the study. The analysis indicated that the combination of GHRP-2, GnRH, and TRH induced the most pronounced activation of growth hormones, thyroid-stimulating hormone, and luteinizing hormone axes, along with potential metabolic effects. These actions were notably absent with the sole administration of GHRP-2 and partially observed with the combination of GHRP-2 and TRH. Please note that GHRP-2 peptide is exclusively available for research and laboratory purposes.

CAS Number
PubChem CID
Molecular Weight
Molecular Formula
Synonyms
Storage (Lyophilized) At 39 Fahrenheit: 2 years At -4 Fahrenheit: 3 years

GHRP-2 (5mg / 10mg)

GHRP-2 is a synthetic peptide designed to mimic the actions of the naturally occurring peptide ghrelin. Ghrelin, originally discovered in the stomach and composed of 28 amino acids, plays a vital role in regulating various physiological processes, including food intake, the release of growth hormone (HGH), and wound healing.

Research on GHRP-2 suggests its multifaceted impacts on the body. It may act on pituitary cells, stimulating the secretion of growth hormone (GH). Additionally, GHRP-2 has shown the potential to interact with the growth hormone release factor (GRF) receptor. Moreover, it may influence calcium channels, promoting the secretion of both calcium and GH through calcium influx. Furthermore, GHRP-2 has been investigated for its ability to stimulate the cAMP pathway and protein kinase C, potentially resulting in increased calcium influx and subsequent growth hormone secretion. These complex mechanisms underline the diverse effects of GHRP-2.

Research and Clinical Studies

GHRP-2 Peptide and GH Activity

A clinical investigation aimed to understand the impact of two synthetic GHRPs, GHRP-2 and Hexarelin (HEX), on the concentrations of growth hormones, prolactin, adrenocorticotropic hormone (ACTH), and cortisol. Two groups of subjects participated: one group aged between 22 and 27 years, and the other between 66 and 73 years. Both groups received correlated concentrations of both peptides. The results indicated a positive correlation between peptide concentration and GH release in the subjects.

GHRP-2 Peptide and Appetite

In a separate clinical study, seven male subjects were divided into two groups, with one group receiving GHRP-2 and the other receiving saline. Following this, they were presented with a buffet meal to assess their food intake. Researchers reported that subjects who received GHRP-2 consumed an average of 36% more food compared to the saline group. Additionally, GH levels exhibited significant increases in the GHRP-2 group when compared to the saline group.

GHRP-2 Peptide and GH Deficiency

The insulin tolerance test (ITT) is a common diagnostic tool for GH deficiency but may pose contraindications. Another clinical study aimed to explore GHRP-2’s potential as an alternative diagnostic resource for GH deficiency. The study involved 135 subjects initially tested via ITT, with 77 demonstrating normal insulin tolerance and 58 showing GH peak levels of less than three. After overnight fasting, all subjects received GHRP-2. Blood samples collected after 2 hours revealed that GH levels peaked after one hour of GHRP-2 administration in all subjects, with reproducible results upon test repetition. Another clinical study investigated the diagnostic properties of GHRP-2 on young subjects with GH deficiency (GHD) compared to conventional compounds. In this study, 24 subjects with GHD were enrolled. All subjects received at least one conventional compound followed by GHRH and GHRP-2. Notably, GHRP-2 administration led to significantly increased serum GH levels in these subjects. Furthermore, 21 subjects who exhibited a robust response to the peptide were subsequently presented with a combination of GHRP-2 and GHRH, resulting in a positive response in their GH levels.

Combination Studies with TRH and GnRH

A clinical study examined subjects with prolonged hypo-somatotropism, hypogonadism, or hypothyroid complications to evaluate the effects of GHRP-2, Thyrotropin-releasing hormone (TRH), and Gonadotropin-releasing hormone (GnRH) compounds. These compounds were administered alone or in combination with GHRP-2. The study included 33 male subjects who received various treatments over 5 days. Serum samples were collected on the first and last nights of the study. The analysis indicated that the combination of GHRP-2, GnRH, and TRH induced the most pronounced activation of growth hormones, thyroid-stimulating hormone, and luteinizing hormone axes, along with potential metabolic effects. These actions were notably absent with the sole administration of GHRP-2 and partially observed with the combination of GHRP-2 and TRH. Please note that GHRP-2 peptide is exclusively available for research and laboratory purposes.

CAS Number 
PubChem CID 
Molecular Weight 
Molecular Formula 
Synonyms 
Storage (Lyophilized)

At 39 Fahrenheit: 2 years

At -4 Fahrenheit: 3 years

Additional information
Size

5mg, 10mg

Related products